Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Fallopian Tube Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Neoplasm Metastasis 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uveal Melanoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Melanoma 1Gastrointestinal Stromal Tumors 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × STA 9090 × Clear all
NCT01039519 2016-03-10

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Synta Pharmaceuticals Corp.

Phase 2 Completed
27 enrolled 22 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡